Compare Amgen, Inc. (AMGN) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs TotalEnergies SE — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while TotalEnergies SE trades at $79.64 (market cap $173.13B). The key difference: Amgen, Inc. and TotalEnergies SE are close in size by market cap, and TotalEnergies SE pays the higher dividend (5.37%). Which is the better fit depends on your goals.
| AMGN | TTE | |
|---|---|---|
Market Cap | $196.12B | $173.13B |
Sector | Health | Energy |
52-Week High | $388.16 | $93.60 |
52-Week Low | $271.18 | $57.39 |
Enterprise Value | $241.41B | $207.27B |
Dividend Yield | 2.77% | 5.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TTE trades at $78.5, up 0.35% today, with a neutral technical signal and mixed earnings history including a Q1 2026 beat. Valuation ratios appear attractive with a P/E of 11.65 and EV/EBITDA of 4.81. Recent news highlights strategic divestments and new LNG shipments, while cash flow trends show stabilization after recent declines.
Outlook is cautiously positive given strong analyst buy ratings (57.58%) and shareholder returns via dividends, but risks include revenue declines, geopolitical exposure, and regulatory pressures. The stock offers value characteristics with moderate growth prospects amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
